1. Introduction {#sec0005}
===============

Infections caused by multi-drug resistant (MDR) pathogens, including *Pseudomonas aeruginosa* are increasing globally. *P. aeruginosa* is often thought of as the prototypic MDR organism as it is capable of developing resistance by utilizing both non-enzymatic, such as modification of the outer membrane protein OprD, and enzymatic processes, which include mutations in chromosomal genes or transferable resistance determinants such as metallo-β-lactamases (MBLs) and extended spectrum β-lactamases (ESBL) [@bib0005]. The spread of MBLs among *P. aeruginosa* and *Enterobacteriaceae* has been rising in the recent years. Among the clinically relevant MBL enzymes is VIM, which was first recovered in Italy in 1997 and manifested resistance to several β-lactam antibiotics, including imipenem with a minimum inhibitory concentration (MIC) of\>128 mg/L [@bib0010]. As a result of these emerging resistance trends and the limited therapeutics options against these MBLs, investigations assessing the clinical implications of resistance as defined by the current *in vitro* criteria are required. To this end, previously conducted studies suggest that for *Enterobacteriaceae*, humanized exposures of carbapenems retain *in vivo* activity against two MBL-producers (NDM and VIM), despite resistant as defined by *in vitro* MICs \[[@bib0015], [@bib0020]\]. In this study, we sought to compare and contrast the effect of VIM production in Enterobacteriaceae and *P. aeruginosa* by characterizing the efficacy of meropenem and comparators, levofloxacin and cefepime, against VIM-producing *P. aeruginosa*.

2. Methods {#sec0010}
==========

The ethical approval was obtained from Institutional Animal Care and Use Committee before the start of the study. Commercially available levofloxacin (Akorn Inc, Lake Forest, IL), meropenem (Hospira Inc, Lake Forest, IL) and cefepime (Sagent, Schaumberg, IL) were acquired from the Hartford Hospital Pharmacy Department (Hartford, CT) to be used during *in vivo* experimentation. All antibiotics were reconstituted according the manufacturers' recommendations and further diluted to the required concentration using normal saline shortly before the experiment.

A total of eight clinical *P. aeruginosa* isolates were tested ([Table 1](#tbl0005){ref-type="table"}). All isolates were frozen at −80 °C in double strength skim milk (Remel, Lenexa, KS) and cultured twice consecutively on trypticase soy agar with 5% sheep blood (BD Biosciences, Sparks, MD) and incubated at 35 °C for 18--24 hours prior to experimentation. Levofloxacin, meropenem, and cefepime MICs were determined using broth microdilution in accordance with Clinical Laboratory Standards Institute (CLSI) methodology using standard analytical powder (Sigma-Aldrich, St. Louis, MO) [@bib0025].

Whole genome sequencing was performed using an Illumina MiSeq desktop sequencer at Walter Reed Army Institute of Research (Silver Spring, MD, USA), as previously described \[[@bib0030], [@bib0035]\]. Multilocus sequence type profiles were determined based on database maintained by the Institut Pasteur (Paris, France) and by NCBI (Bethesda, MD, USA), respectively. The study was reviewed and approved by the Institutional Animal Care and Use Committee at Hartford Hospital, Hartford, CT and animals were kept in consistence with National Research Council's recommendations and given nutrition *ad libitum.* ICR mice with an average weight of 22 g were obtained from Harlan Laboratories (Indianapolis, IN) and utilized throughout. Neutropenia was induced with cyclophosphamide 150 mg/kg and 100 mg/kg at 4 days and 1 day prior to inoculation, respectively. In addition, uranyl nitrate 5 mg/kg was administered three days prior to inoculation to produce a controlled degree of renal impairment. The study animals were inoculated in each thigh with 0.1 ml of bacterial suspension containing 10^7^ CFU/ml of the test isolate in normal saline and antibiotic administration started 2 hours later. Humanized doses of levofloxacin 500 mg q24 h designed to achieve an AUC of 42--53 mg.h/L [@bib0040], meropenem 2 g q8 h as 30-min infusion [@bib0045] and cefepime 2 g q8 h as 30-min infusion [@bib0050], as previously developed and validated by our group, were administered as 0.2 ml subcutaneous injections to groups of three animals over 24 hours. The β-lactams regimens were designed to simulate the pharmacodynamic profile observed in humans given these regimens ([Table 2](#tbl0010){ref-type="table"}). As required to optimize the use of animals in research, repeated PK studies were not done in our current investigation because exposure profile validation was defined previously in our laboratory on the same mice species. A group of three mice was harvested at the beginning of dosing to serve as 0 hour controls and another group was given 0.2 ml subcutaneous normal saline as frequently as the most dosed antibiotic for each isolate. At the end of 24-hour study period, treatment and control animals were euthanized by CO~2~ exposure followed by cervical dislocation; thighs were excised from sacrificed animals, homogenized in 5 ml of normal saline (mini bead-beater, BioSpec Products, Bartlesville, OK), and serially diluted and plated on trypticase soy agar with 5% sheep blood for counting of bacterial densities. Efficacy was calculated as the change in bacterial density (log~10~ CFU) of intervention groups compared with the 0 hour control group. To assure enzyme production across experimentation, thigh homogenates from 0-hour and 24-hour control animals, as well as, meropenem treated mice were plated on agar containing meropenem concentrations equivalent to the MIC of the test strain.

3. Results {#sec0015}
==========

A list of study isolates along with their respective MIC and genotypes is shown in [Table 1](#tbl0005){ref-type="table"}. The growth (mean ± SD) of the 0h-control group was 5.00 ± 0.36 log~10~ CFU while that of 24h-control group was 8.52 ± 0.47. Levofloxacin ([Fig. 1](#fig0005){ref-type="fig"}) exhibited a lack of activity against all tested isolates as predicted based on the phenotypic profile of the test strains. Similarly, humanized cefepime had minimal activity against the 8 isolates, consistent with the inability of this regimen to achieve pharmacodynamic targets ([Table 2](#tbl0010){ref-type="table"}). Conversely, meropenem was predictably active against PSA1550 and PSA1480 as their MIC profiles resulted in sufficiently high free drug exposures. Moreover, while the *f*T\> MIC of PSA1475 was reduced (5--18%), considerable efficacy was noted for this isolate. Activity was also observed for PSA1478 (MIC = 128 mg/L, *f*T\> MIC = 0--5%), on the other hand there was no activity against PSA 1465 with the same MIC. No activity was observed for the remaining 3 strains with MIC of 512 mg/L. All isolates recovered from the mice after treatment showed growth on meropenem containing plates, thus confirming the presence of enzyme mediated activity throughout the *in vivo* exposure period.

4. Discussion {#sec0020}
=============

The acquisition of resistance by *P. aeruginosa* with reports of emerging metallo-β-lactamases worldwide is a growing challenge in nosocomial infections and efforts are needed to describe appropriate treatment options [@bib0055]. In the current *in vivo* murine study employing humanized exposures, we found that the *in vitro* MIC of VIM-producing *P. aeruginosa* was reflective of the *in vivo* activity of levofloxacin, cefepime, and meropenem. These observations in *P. aeruginosa* were unlike what we have previously demonstrated with Enterobacteriaceae \[[@bib0015], [@bib0020]\]. As such, these current data suggest that for VIM-producing *P. aeruginosa* the expected clinical efficacy of monotherapy will be governed by the achievement of an optimized pharmacodynamic profile according to the principle driver (i.e., *f*T\> MIC, AUC/MIC) for the class of compounds under consideration.

While the concept of pharmacodynamic predictability among antimicrobials is certainly not novel [@bib0060], previous studies by our group with carbapenemase-producing Enterobacteriaceae have yielded varied results, particularly for the β-lactams \[[@bib0015], [@bib0020], [@bib0065], [@bib0070]\]. Namely, while the activity of carbapenems and cephalosporins were pharmacodynamically concordant against KPC-producing strains, activity against MBL-producers (i.e., NDM or VIM), particularly for the carbapenems, was observed *in vivo*, despite elevated *in vitro* MICs. While evidence seems to suggest that MBLs have a diminished impact *in vivo*, the discordance between observations against MBL-producing Enterobacteriaceae and *P. aeruginosa* is hypothesized to be due to the myriad of other resistance mechanisms present in *P. aeruginosa*, such as porin or efflux proteins [@bib0005]. This is reflected in the current study by the observation that two isolates with the same MIC and enzymatic resistance genotypes showed opposite killing patterns *in vivo,* thus the overall contribution of the enzyme mediated resistance *in vivo* appears blunted in the presence of alternative mechanisms.

While we found the tested agents to be generally ineffective against resistant strains, a previous study of a single VIM-producing *P. aeruginosa* in the rat pneumonia model found that high doses of imipenem, cefepime, ceftazidime, piperacillin/tazobactam and aztreonam (MICs were 128, 64, 256, 16 and 0.25 mg/L, respectively) were effective in reducing bacterial loads *in vivo* despite *in vitro* resistance [@bib0075]. While the use of human simulated exposures is mentioned by the authors, the free-drug profile of their treatment regimens in blood and lung are not provided; therefore direct comparisons between the two studies are difficult.

The available clinical data have repeatedly shown poor outcomes for patients infected with multi-drug resistant *P. aeruginosa* producing VIM enzymes. Assessments of appropriate empiric and definitive treatment are challenging given that many of these organisms are resistant to almost all the antibiotics, except colistin [@bib0080]. Moreover, in some cases these organisms are pan-drug resistant, with combinations of colistin and β-lactams being reported as viable [@bib0085].

Unlike previous observations with MBL-producing Enterobacteriaceae, we found that the MIC of the infecting VIM-producing *P. aeruginosa* predicted *in vivo* efficacy of humanized cefepime and meropenem.

5. Conclusion {#sec0025}
=============

Given the high rates of resistance among these VIM-producing *P. aeruginosa* and the resultant poor pharmacodynamics profiles treatment with monotherapy does not appear to be a viable option for a large proportion of these strains and further emphasizes the need for novel compounds targeted at these difficult pathogens.
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###### 

List of the tested isolates with their respective genotypes and MICs.

Table 1

  Clinical isolates   β-lactamases encoded            MIC (mg/L)           
  ------------------- ------------------------------- ------------ ------- -----
  PSA 1550            VIM-1, OXA-10, OXA-50           32           64      4
  PSA 1480            VIM-2, OXA-2, OXA-10, OXA-50,   64           32      16
  PSA 1475            VIM-1, OXA-50,                  8            \>512   64
  PSA 1465            VIM-1, OXA-50,                  \>64         512     128
  PSA 1478            VIM-1, OXA-50,                  \>64         256     128
  PSA 1466            VIM-2 OXA-4, OXA-50,            \>64         256     512
  PSA 1476            VIM-1, OXA-50,                  16           \>512   512
  PSA 1549            VIM-6, OXA-10, OXA-50           \>64         256     512

PSA: P. aeruginosa.

LEV; levofloxacin, FEP; cefepime, MER; meropenem.

European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints:

Levofloxacin; susceptible ≤ 1 mg/L.

Cefepime; susceptible ≤ 8 mg/L.

Meropenem; susceptible ≤ 8 mg/L.

Clinical Laboratory Standards Institute (CLSI) breakpoints:

Levofloxacin; susceptible ≤ 2 mg/L.

Cefepime; susceptible ≤ 8 mg/L.

Meropenem; susceptible ≤ 4 mg/L.

###### 

Expected free drug time above the minimum inhibitory concentration (MIC) at different values of MIC for cefepime and meropenem.

Table 2

        *f*T\> MIC(%)   
  ----- --------------- ----
  4     100             58
  8     83              45
  16    65              30
  32    38              18
  64    20              5
  128   1               0

Adapted from [@bib0045] and [@bib0050].
